Market revenue in 2023 | USD 478.1 million |
Market revenue in 2030 | USD 1,263.3 million |
Growth rate | 14.9% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase IV |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.26% in 2023. Horizon Databook has segmented the France cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
France followed Germany in terms of market share accounting for 21.0% of the market share in 2021. This is attributed to various strategic initiatives undertaken by market players in France. France has an ideal environment to conduct clinical trials owing to the presence of numerous scientific and medical resources related to this field.
Specialized expertise and infrastructure, such as oncology centers, clinical investigation centers, national clusters & networks, as well as clinical research centers, are improving the demand for clinical trials in France. In addition, the French government is undertaking active measures to reduce the approval time for drugs in clinical trials, which is likely to have a positive impact on the market.
An efficient healthcare and reimbursement system, experience in cell and gene therapy clinical trials since the 1980s, and a large patient pool made the country attractive for outsourcing Cell and Gene Therapy Clinical Trials. There are hospitals specializing in managing patients undergoing Cell and Gene Therapy Clinical Trials across the country.
Horizon Databook provides a detailed overview of country-level data and insights on the France cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into France cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account